CKD patients with hypertension were treated with calcium-channel blockers, β blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and selective α1 adrenergic receptor blockers, and there was no difference in the distribution of these drug between groups. This evidence concerns the gene ACE and chronic kidney disease.